SCHEMBL2383449

SCHEMBL2383449

COc1cc(F)c2oc3ccc(Br)c(F)c3c(=O)c2c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
HPGD P15428 4/20 0.42
KDM4E B2RXH2 3/20 0.42
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.42
CASP3 P42574 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
MAOA P21397 9/20 0.41
MAOB P27338 5/20 0.41
ACHE P22303 1/20 0.41
MGAM O43451 1/20 0.40
GPR35 Q9HC97 1/20 0.38
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2371396 0.83 ALDH1A1 (0.65) ALDH1A1HPGDKDM4EMAPTNPC1
SCHEMBL2384098 0.81 ALDH1A1 (0.58) ALDH1A1HPGDKDM4EMAPTNPC1
SCHEMBL8515753 0.81 MAPT (0.50) ALDH1A1HPGDKDM4EMAPTNPC1
SCHEMBL2370587 0.81 MAPT (0.54) ALDH1A1HPGDKDM4EMAPTNPC1
SCHEMBL2370815 0.80 NPC1 (0.45) ALDH1A1HPGDKDM4EMAPTNPC1
SCHEMBL2381941 0.77 GPR35 (0.41) ALDH1A1MAPTMAOAMGAMGPR35
SCHEMBL2371020 0.69 ALDH1A1 (0.69) ALDH1A1HPGDKDM4EMAPTNPC1
SCHEMBL20349979 0.68 MAOA (0.50) ALDH1A1HPGDKDM4EMAPTNPC1
SCHEMBL19743740 0.65 GPR35 (0.63) ALDH1A1KDM4EGPR35
SCHEMBL29785358 0.65 EGFR (0.48) ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP ALDH1A1 572/4885HPGD 2431/4885KDM4E 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.